• First-generation kinase inhibitors directed against oncogenic drivers such as BCR-ABL fusions (imatinib), EGFR mutations (erlotinib and gefitinib), and ALK rearrangements (crizotinib) have demonstrated vast improvements over cytotoxic chemotherapy in chronic myelogenous leukemia and kinase-driven non-small cell lung cancer (NSCLC), respectively ( 1-4 ). (aacrjournals.org)
  • This population-based study included 2,662 patients diagnosed with CML in the Swedish Cancer Registry who were monitored until death, censoring, or the end of follow-up. (hematology.org)
  • Ponatinib was approved by the US FDA on December 14, 2012, for patients with resistant or intolerant CML and Ph+ ALL, based on results of the PACE phase II trial reported days earlier at the annual ASH meeting. (wikipedia.org)
  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. (springer.com)
  • Importantly, LSC subpopulations with myeloid and proliferative molecular signatures are proportionally reduced at a higher extent in response to TKI therapy compared with subfractions displaying primitive and quiescent signatures. (bloodjournal.org)
  • The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. (amedeo.com)
  • One way to accomplish this is to emphasize phase IV postmarketing, hypothesis-driven clinical trials with biological characterization that would permit an accurate definition of the association of low-prevalence gene alterations with toxicity or response in large cohorts. (aacrjournals.org)
  • In the phase I clinical trial of crizotinib, a radiographic tumor response rate of 55% was observed in ALK rearranged NSCLC patients ( 2 ). (aacrjournals.org)